Aktis Oncology Inc (nasdaq:AKTS) Share Price

Company Profile

Business description
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
Contact
17 Drydock Avenue
Suite 17-401
BostonMA02210
USA
T: +1 617 461-4023
https://www.aktisoncology.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
79

Recommended

Trading at an 18% discount, this wide-moat stock is a rare find.

Malik Ahmed Khan, CFA | 22 September 2026

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.

Jacob Robbins | 21 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,866.10	20.50	0.23%
CAC 40	8,077.80	3.63	-0.04%
DAX 40	25,408.64	142.11	0.56%
Dow JONES (US)	51,828.62	478.64	0.93%
FTSE 100	10,695.25	15.26	0.14%
HKSE	24,704.65	194.56	0.79%
NASDAQ	27,068.72	129.34	0.48%
Nikkei 225	66,333.53	30.67	-0.05%
NZX 50 Index	13,823.16	12.05	0.09%
S&P 500	7,743.41	39.28	0.51%
S&P/ASX 200	8,697.00	32.00	0.37%
SSE Composite Index	3,824.55	63.83	-1.64%